Showing 2,371 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

HIV treatment

Mozambique: Half a Million HIV-Positive People Abandon Anti-Retroviral Treatment

Editor's pick
AllAfrica
29 July 2022
New & experimental HIV treatments

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

Editor's pick
Gilead Sciences press release
28 July 2022
Adherence

Motivational Interviewing May Increase Antiretroviral Therapy Adherence in Patients With HIV

Editor's pick
Infectious Disease Advisor
22 July 2022
PrEP

PrEP State of the Union: Adherence, Access, Uptake Issues

Editor's pick
Contagion Live
22 July 2022
Treatment outcomes & life expectancy

Risk of Mortality Similar Between Most First-Line Antiretroviral Regimens for HIV

Editor's pick
Infectious Disease Advisor
11 July 2022
The search for a cure

People Who Start HIV Treatment With High CD4s Have a Smaller Viral Reservoir

Editor's pick
POZ
7 July 2022
New & experimental HIV treatments

Fostemsavir Plus Optimized Background Therapy May Be Viable for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
30 June 2022
New & experimental HIV treatments

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Editor's pick
Gilead Sciences press release
28 June 2022
Injectable & long-acting HIV treatment

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Editor's pick
Gilead Sciences press release
25 June 2022
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120

Editor's pick
GlobeNewswire (press release)
13 June 2022
The search for a cure

Combination Anti-HIV Antibody Infusions Suppress Virus for Sustained Period

Editor's pick
HIV.gov
6 June 2022
Treatment guidelines

South Africa: Over 3 million people on new HIV drug, but not all smooth sailing

Editor's pick
Spotlight
1 June 2022
Drug interactions & pharmacokinetics

ViiV Healthcare has obtained marketing approval for the first and only complete long-acting treatment for HIV in Japan

Editor's pick
ViiV press release
31 May 2022
Adherence

Ingestible sensor helps identify PrEP adherence patterns

Editor's pick
Healio
30 May 2022
HIV treatment for children & young people

HHS Updates Pediatric HIV Guidelines

Editor's pick
Infectious Disease Special Edition
18 May 2022
New & experimental HIV treatments

FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

Editor's pick
Gilead Sciences press release
18 May 2022
Cancer

Full-Dose Chemotherapy Regimen Appears Safe for Patients With HIV and Cancer

Editor's pick
Oncology Nurse Advisor
16 May 2022
Treatment guidelines

BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 - consultation open

Editor's pick
British HIV Association (BHIVA)
10 May 2022
Drug-resistant TB

Rapid communication: Key changes to the treatment of drug-resistant tuberculosis

Editor's pick
World Health Organization
4 May 2022
Climate change

Climate change reduces HIV treatment adherence in Africa

Editor's pick
Africa Health Research Institute
29 April 2022
People with limited treatment options

Theratechnologies to Focus Its Commercialization Activities on the North American Territory

Editor's pick
Theratechnologies press release
28 April 2022
Ageing & HIV

Polypharmacy Common Among Patients Aged 65 or Older With HIV

Editor's pick
Medscape (requires free registration)
28 April 2022
Changing treatment

‘The Devil You Know’: Many People Over 50 Are Taking Outdated ART, Despite Side Effects

Editor's pick
TheBodyPro
27 April 2022
Bad science & bogus treatments

WHO Warns of Dangers of Health Misinformation Across Social Media Following Elon Musk’s $44 bn Twitter Acquisition 

Editor's pick
Health Policy Watch
27 April 2022